Gilead's Livdelzi shows strong results in liver disease study, normalizing key liver marker in PBC patients.

Gilead Sciences announced positive Phase 3 IDEAL study results for Livdelzi (seladelpar) in treating primary biliary cholangitis (PBC). The drug significantly normalized alkaline phosphatase (ALP), a critical liver disease marker, in patients with inadequately controlled PBC after 52 weeks. This supports Livdelzi's use in a broader patient group often underrepresented in trials. Gilead plans to present full data at a medical congress and engage regulators, advancing treatment options for PBC patients.